A Rare Cause of Hypergonadotropic Hypogonadism: Transaldolase Deficiency in Two Siblings

Yildiz M et al. Hypogonadism due to Transaldolase Deficiency

Melek Yildiz1, Zerrin Onal1, Gozde Yesil1, Tugce Goksu Kabil1, Guven Toksoy2, Sukran Poyrazoglu3, Firdevs Bas1, Ozlem Durmaz2, Feyza Darendeliler1
1Department of Pediatric Endocrinology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
2Department of Medical Genetics, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
3Department of Gastroenterology, Hepatology and Nutrition, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey

What is already known on this topic?

- Transaldolase deficiency is a multisystemic disease which is characterized by intrauterine growth restriction, dysmorphism, abnormal skin, cytopenia, hepatosplenomegaly, liver cirrhosis, endocrine problems, renal and cardiac abnormalities.
- Several endocrine system problems such as abnormal external genitalia, primary hypothyroidism, short stature, bone abnormalities and hypergonadotropic hypogonadism may occur in transaldolase deficiency.

What this study adds?

- Gonadal dysfunction with hypergonadotropic hypogonadism may occur in both girls and boys with transaldolase deficiency.
- Hypergonadotropic hypogonadism may become hormonally apparent in adolescence in girls with transaldolase deficiency although puberty starts on time.
- Transaldolase deficiency should be included in the differential diagnosis of cryptogenic cirrhosis and multisystemic involvement especially if concomitant hypergonadotropic hypogonadism is assigned.
- Patients with transaldolase deficiency should be evaluated for gonadal functions especially during puberty.

Abstract

Transaldolase deficiency is a rare inborn autosomal recessive disorder caused by biallelic mutations in the TALDO1 gene. It is characterized by intrauterine growth restriction, dysmorphism, abnormal skin, cytopenia, hepatosplenomegaly, liver cirrhosis, endocrine problems, renal and cardiac abnormalities. We present two siblings of Turkish origin with early-onset form of transaldolase deficiency and hypergonadotropic hypogonadism in both sexes. The girl (index) was followed-up with cryptogenic cirrhosis, leukopenia and thrombocytopenia, skin abnormalities, congenital heart defects, hypercalciuria, proteinuria, chronic kidney disease throughout childhood. She developed hypergonadotropic hypogonadism in adolescence period. Whole exome sequencing due to the multisystemic involvement revealed a previously described homozygous inframe deletion in TALDO1 gene. Her brother was born as a small for gestational age baby and was also followed-up with cryptogenic cirrhosis since his infancy, together with cytopenia, congenital heart defects, bilateral cryptorchidism, short stature, hypercalciuria, proteinuria and chronic kidney disease in childhood. He presented with testicular microlithiasis and hypergonadotropic hypogonadism in adolescence. Sanger sequencing of TALDO1 gene confirmed the presence of the same homozygous deletion with his sister. His mother was found to be a heterozygous carrier for this deletion. We describe two patients with multisystemic involvement since neonatal period who presented with an additional hypergonadotropic hypogonadism in adolescence. The diagnosis of transaldolase deficiency should be kept in mind for these patients, and they must be evaluated for gonadal functions especially during puberty.

Keywords: Transaldolase deficiency, hypergonadotropic hypogonadism, whole exome sequencing, TALDO1

Case Report

Patient 1

Introduction

Transaldolase is a key enzyme in pentose phosphate pathway (PPP) which is an alternative route for glucose oxidation. Glucose metabolism through PPP has two important functions: formation of ribose 5-phosphate for the synthesis of essential biomolecules, such as adenosine triphosphate (ATP), RNA, and DNA, and formation of NADPH for biosynthetic reactions and neutralization of reactive oxygen intermediates. In the absence of this enzyme, some intermediate products such as polyols and seven-carbon sugars accumulate in body fluids, mostly in urine (1). Transaldolase deficiency is first described in 2001 in a Turkish girl with prominent liver involvement during early infancy (2). It is a rare inborn autosomal recessive disorder caused by biallelic mutations in the TALDO1 gene and characterized by intrauterine growth restriction (IUGR), dysmorphism, abnormal skin, cytopenia, hepatosplenomegaly, liver cirrhosis, endocrine problems, renal and cardiac abnormalities (3). Patients may exhibit either an early-onset presentation (prenatally or before 1 month of age) with severe symptoms during the neonatal period or a relatively milder late-onset presentation.

Evaluation of endocrine system in patients with transaldolase deficiency recently revealed abnormal external genitalia, primary hypothyroidism, short stature, bone abnormalities and gonadal dysfunction with hypergonadotropic hypogonadism (3). Here, we present two siblings of Turkish origin with early-onset form of transaldolase deficiency and hypergonadotropic hypogonadism with an overview of multisystemic manifestations throughout childhood in both sexes. Molecular diagnosis was established with whole exome sequencing in the index due to the multisystemic involvement, just before transition.
A 7.617 year-old girl (index) was referred to pediatric endocrinology clinic due to development of pubic hair. She was born after an uneventful pregnancy at term with a birth weight of 2,800 g (-1.44 SD) and birth length of 49 cm (-0.51 SDS). She was the second child of healthy, consanguineous parents of Turkish origin. There was no family history of infertility. Soon after newborn period, she underwent diagnostic work-up due to splenomegaly, elevated transaminase levels, direct hyperbilirubinemia, and prolonged coagulation tests. She was diagnosed with chronic liver disease of unknown cause. At the age of 2.912 years, the diagnosis of cryptogenic liver disease was established with liver biopsy. A diagnosis of cryptogenic cirrhosis was made as a result of liver biopsy and etiological investigations. She was followed up for portal hypertension and managed conservatively for gastrointestinal bleeding. Bone marrow aspiration for evaluation of possible storage diseases exhibited hypercellular and heterogeneous bone marrow associated with hypersplenism but no evidence of storage cells. She was also regularly followed-up due to secundum atrial septal defect (ASD), mitral valve prolapse, mild dilatation of the aortic root, and aortic regurgitation since infancy. She had primary nocturnal enuresis, history of a kidney stone due to hypercalcuria, and proteinuria. Further, she was under medication due to attention-deficit/hyperactivity disorder (ADHD). Endocrine pancreas functions were normal, with blood glucose, insulin and Hba1c in normal ranges. Clinical manifestations are given in Table 1.

At the age of 13 years, he was diagnosed with membranous glomerulopathy and after adolescence, with chronic kidney disease. He did not have hepatic decompensation throughout childhood period and liver transplantation wasn't needed. Sanger sequencing of TALDO1 have hepatic decompensation throughout childhood period and liver transplantation wasn't needed. Sanger sequencing of TALDO1 gene was detected (NM_006755.2; c.512-6/12). This mutation was previously reported in a Turkish girl (2).

Physical examination at referral revealed a body weight of 19.8 kg (-1.34 SDS), height of 122 cm (-0.32 SDS) (target height 160 cm (-0.52 SDS), triangular small face, microretrognathia, flat nasal bridge, long eyelashes, high palate, diffuse telangiectasias, thin and dry skin, hemangiomas, and a 3 cm palpable splenomegaly. Neurodevelopmental milestones and systemic examination were otherwise normal. He had Tanner stage 2 pubic hair but no breast development or clitoromegaly. Pubertal examination findings, and pubertal hormone administration and afterwards are given in Table 2. Laboratory investigation for premature adrenarche revealed normal levels of dehydroepiandrosteronedione sulphate and total testosterone. Slightly elevated 17-hydroxyprogesterone (1.29 ng/mL) and 17-dehydroepiandrosterone (1.5 ng/mL) levels prompted us to perform a 250μg adrenocorticotropin hormone (ACTH) stimulation test which resulted in normal cortisol response and adrenal precursor concentrations. Thyroid hormone levels were within normal limits. Bone age was consistent with 8.915 SDS, and slightly advanced. During her follow-up, breast development started at 9.617 years and pubertal development proceeded with mean age of 12 years. Inappropriately increased follicle stimulating hormone (FSH) levels for her pubertal stage were consistent with hypergonadotropic state with menarche. Afterwards, primary ovarian insufficiency (POI) became apparent clinically with secondary amenorrhea and hormonally with low anti-mullerian hormone (AMH) levels (<0.08 ng/mL). Pelvic ultrasound imaging revealed a pubertal uterus volume of 9 mL (13.2x3.53 mm) and ovarian volumes of 2.4/1.7 mL. Diagnostic work-up for the etiology of POI resulted in final 46,XX karyotype, negative genetic testing for the fragile X mental retardation 1 (FMR1) premutation (29/32 CCG repeats), negative 21-hydroxylase antibody testing, and negative screening for reducing substances in urine. There had been no signs of autoimmune adrenal disease nor history of a cytotoxic treatment to ovaries. She was evaluated for the consequences of estrogen deficiency. Dual energy x-ray absorptiometry (DEXA) scan revealed a low L1-L4 bone mineral density of 0.782 g/cm³ (Z score -2.5). Since there had been no history of any bone fracture, she was put on calcium and vitamin D prophylaxis. Because of known chronic liver disease, transdermal estrogen and gestrinone regimen was preferred as hormone replacement therapy.

At the age of 15 years, she was diagnosed with chronic kidney disease. At the age of 16.3 years, a hyperchoic nodular mass on cirrhotic liver was detected on ultrasonography and magnetic resonance imaging (MRI). Due to the suspicion of hepatocellular carcinoma, she underwent living related liver transplantation from his father. The histopathological assessment of the explanted liver did not confirm the diagnosis of hepatocellular carcinoma. The features of nodular cirrhosis, focal necroinflammatory lesions, and microvascular steatosis were described. Owing to the multisystemic involvement, chromosomal microarray analysis and whole exome sequencing (WES) was perfomed. Xen® Exome Research Panel v1.0 in NovaSeq Platform for exome sequencing and CytoScan 750K Array kit in Affymetrix Platform for microarray analysis were used. A previously described homoyzogenous deletion in exons 6 of TALDO1 gene was detected (NM_006755.2;c.512-514delCTT; p.Ser171del). This mutation was previously reported in a Turkish girl (2).

At the age of 13 years, he was diagnosed with membranous glomerulonephritis and after adolescence, with chronic kidney disease. He did not have hepatic decompensation throughout childhood period and liver transplantation wasn’t needed. Sanger sequencing of TALDO1 gene was detected (NM_006755.2; c.512-6/12). This mutation was previously reported in a Turkish girl (2).

**Patient 2**

Patient 2, the older brother of Patient 1, was referred to pediatric endocrinology clinic due to bilateral cryptorchidism at the age of 9 years. He was born after an uneventful pregnancy at term with a birth weight of 2,500 g (-2.94 SDS), as a small for gestational age baby. He was also investigated for chronic liver disease since newborn period, and the diagnosis of cryptogenic cirrhosis was established at the age of 4.72 years. He had portal hypertension, esophageal varices, leukopenia, and thrombocytopenia. He was operated for secundum ASD. He had also investigated for chronic liver disease since newborn period, and the diagnosis of cryptogenic cirrhosis was established at the age of 4.72 years. He had portal hypertension, esophageal varices, leukopenia, and thrombocytopenia. He was operated for secundum ASD. He had primary nocturnal enuresis, hypercalcemia, and proteinuria. Clinical manifestations of both siblings are given in Table 1. Physical examination at referral revealed a body weight of 20.8 kg (-2.23 SDS), height of 122 cm (-1.83 SDS) (target height 173 cm (-0.52 SDS)), sitting height/height ratio 0.54, triangular small face, microretrognathia, diffuse telangiectasias, thin and dry skin, 3/6 systolic murmur, and a 4 cm palpable splenomegaly. Neurodevelopmental milestones were normal. His pubertal development was consistent with Tanner stage 1, both testes were nonpalpable, and stretched penile length was 4 cm (Normal penile length for age: >4.72 cm). FSH, luteinizing hormone (LH) and testosterone concentrations were within prepubertal ranges. Testicular ultrasonography revealed bilateral small testes (0.50 cm) and normal blood flow. Luteinizing hormone (LH) (6.40 mL/m² per minute normal) and follicle stimulating hormone (FSH) stimulation test revealed gonadotropin deficiency (15.87 IU/L/day, for 3 days) revealed no testosterone response. He underwent bilateral orchioxyphy due to bilateral undescended testes soon after his admission. Pubertal examination findings, and pubertal hormones at admission and afterwards for both siblings are given in Table 2. During his follow-up he was evaluated for short stature and low annual growth rate, when he was 13. Thyroid hormone levels were within normal limits. The growth hormone (GH) stimulation test revealed GH deficiency with peak GH levels of 4.96 ng/mL and 5.37 ng/mL. MRI scan of hypophysis was normal. During the investigations for delayed puberty at the age of 14, hypergonadotropic hypogonadism was detected. Inhibin-B level was 10/12 (Z score -2.5). Since there had been no history of any bone fracture, she was put on calcium and vitamin D prophylaxis. Because of known chronic liver disease, transdermal estrogen and gestrinone regimen was preferred as hormone replacement therapy.

At the age of 15 years, she was diagnosed with chronic kidney disease. At the age of 16.3 years, a hyperchoic nodular mass on cirrhotic liver was detected on ultrasonography and magnetic resonance imaging (MRI). Due to the suspicion of hepatocellular carcinoma, she underwent living related liver transplantation from his father. The histopathological assessment of the explanted liver did not confirm the diagnosis of hepatocellular carcinoma. The features of nodular cirrhosis, focal necroinflammatory lesions, and microvascular steatosis were described. Owing to the multisystemic involvement, chromosomal microarray analysis and whole exome sequencing (WES) was perfomed. Xen® Exome Research Panel v1.0 in NovaSeq Platform for exome sequencing and CytoScan 750K Array kit in Affymetrix Platform for microarray analysis were used. A previously described homoyzogenous deletion in exons 6 of TALDO1 gene was detected (NM_006755.2;c.512-514delCTT; p.Ser171del). This mutation was previously reported in a Turkish girl (2).

Hypergonadotropic hypogonadism was reported in 18% of transaldolase deficient patients in a study performed by a retrospective questionnaire and literature review of 34 patients from 25 families (3). All these 6 reported patients were of early-onset type. Recently, a boy with a late-onset presentation of transaldolase deficiency was reported with the prominent clinical finding of hypergonadotropic hypogonadism for the first time (4). Several hypotheses have been proposed to explain the mechanism of gonadal dysfunction in patients.
with transaldolase deficiency. As cirrhosis has been suggested to result from increased cell death of hepatocytes, gonadal insufficiency was thought to occur due to cell damage. Enzyme-activity and metabolic studies of transaldolase deficient lymphoblasts had revealed coordinated changes in mitochondrial homeostasis, oxidative stress, and Ca\textsuperscript{2+} fluxing (5). Shortage of NADPH and antioxidant glutathione lead to decreased mitochondrial transmembrane potential and reduced ATP/ADP ratio in the liver of mice lacking transaldolase (TALDO1\(-/-\)) (6). Increased levels of reactive oxygen intermediates and depleted neutralization together with toxic accumulation of C5 polyols and seven-carbon sugars might lead to apoptosis, and direct damage to gonadal cells in these patients (1). On the other hand, decrease in the ratio of NADPH/NADP might be a cause for the abnormal gonadal steroid hormone biosynthesis (5). TALDO1 gene is significantly expressed in almost all tissues in the body. It has relatively higher expression in bone marrow and gastrointestinal tract, while it is expressed to some extend in the ovary and testis (7). Therefore, oxidative stress due to dysfunction of PPP to metabolize glucose could account not only for defects in liver tissue but bone marrow but also for gonadal damage. Patients should also be followed carefully in terms of other system dysfunctions in meanwhile.

The phenomenon of occurrence of substances such as polyol and a sugar phosphate due to an enzyme deficiency in a pathway is also seen in galactosemia due to galactose-1-phosphate uridytransferase deficiency (8). Ovarian failure in galactosemia is suggested to be due to direct toxic effect of galactose or its metabolites on ovarian parenchyma. Gonadal dysfunction is acquired and vary in severity with the age of the patient at onset (9). However, clinically significant gonadal dysfunction is not reported in boys, except for cryptorchidism. There has been evidence for both mild Sertoli and Leydig cell dysfunction in the testes, but these would have little impact on fertility (10). On the other hand, gonadal dysfunction and hypergonadotropic hypogonadism has been reported in both sexes with transaldolase deficiency (3). Fertility of spermatozoa depends on the maintenance of the mitochondrial transmembrane potential and regulated by an oxidation-reduction equilibrium of reactive oxygen intermediates. In a rat study, TALDO\(1\)/-/- male mice revealed defective forward motility of spermatozoa exhibiting transaldolase deficiency as a cause of sperm dysmotility and male infertility (11). In Patient 2, low inhibin B concentrations suggested Sertoli cell dysfunction and infertility in the upcoming years. But the pathogenesis of gonadal dysfunction in males has not yet been entirely elucidated.

In this report, the girl (Patient 1) with transaldolase deficiency had a spontaneous pubertal onset on time with gonadotropins in normal range. She had a normal pubertal development but hypergonadotropic hypogonadism became hormonally apparent at the time of menarche, and several years prior to the liver transplantation. On the contrary, puberty of the boy (Patient 2) did not begin until normal time interval, and no testicular enlargement was observed as the previously reported boy with late-onset presentation (4). This might be either due to the primary cellular damage in testis or damage to gonadal tissue due to late orchiopexy. Furthermore, persistence of these two conditions may have exacerbated the clinical presentation. The onset and timing of the damage causing gonadal dysfunction in transaldolase deficiency in both sexes remains unclear as for ovarian dysfunction in galactosemia (12). Further studies are needed to understand if transaldolase expression in ovary and testis differ, and if gonadal cells are affected in a different manner from the increased levels of reactive oxygen intermediates and oxidative stress.

Short stature was described in some patients with transaldolase deficiency with a concomitant IGF-1 deficiency in a few (3). IGF-1 deficiency has been speculated to be due to delayed puberty, malnutrition, or liver disease. Evidence of chronic systemic diseases in transaldolase deficiency could further contribute to poor growth. Short stature and IGF-1 deficiency observed in Patient 2 was possibly due to the combination of all these mechanisms. Growth hormone therapy has not been considered due to underlying chronic diseases of unknown etiology in those cases.

The mutation in our patients was same as in the first reported Turkish girl (2) with transaldolase deficiency. This girl was evaluated for an enlarged clitoris, but dehydroepiandrosterone, androstenedione, and testosterone in serum were normal. Our index was also evaluated for signs of hyperandrogenism, but the final diagnosis was premature adrenarche with the slightly elevated adrenal precursors. The disease may exhibit variable expressivity or intrafamilial phenotypic variability as previously reported (13). Follow-up of these patients is of great importance since deficits in several organ systems could appear due to damaging oxidative stress.

In conclusion, patients with cryptogenic cirrhosis and multisystemic involvement should be evaluated for gonadal functions especially during puberty. Transaldolase deficiency might be included in the differential diagnosis of these patients especially if concomitant hypergonadotropic hypogonadism is assigned. In patients with transaldolase deficiency, puberty can spontaneously start but one should be aware of the possibility of developing hypergonadotropic hypogonadism in follow-up. Cryptorchidism might be an alarming symptom. Early diagnosis of these patients might give an opportunity for tissue cryopreservation to preserve fertility in the long term. Our cases got the definitive diagnosis of transaldolase deficiency with WES, after years of follow-up with multisystemic involvement throughout childhood. Testing for pathogenic variants in TALDO1 gene might be considered earlier in these patients.

Acknowledgments
The authors thank the patients and their parents for their consent to publication.

Statement of Ethics
Ethical approval is not required for this retrospective case report in accordance with our national guidelines. However, written informed consent was obtained from the parents for publication of this case report.

Conflicts of Interest Statement
The authors have no conflicts of interest to declare regarding this subject.

Funding Sources
There is no external funding relevant to this case report.

Author Contributions
M.Y. and T.G.K. wrote the first draft of the manuscript and tables. Z.O., G.Y., G.T., S.P., F.B., O.D., and F.D. revised the manuscript and agreed upon the final version. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Data Availability Statement
All data generated or analyzed during this study are included in this paper. Further inquiries can be directed to the corresponding author.

References

Table 1. Clinical manifestations of two siblings throughout childhood

<table>
<thead>
<tr>
<th>Clinical features</th>
<th>Patient 1 (index)</th>
<th>Patient 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>Female</td>
<td>Male</td>
</tr>
<tr>
<td>Molecular Diagnosis</td>
<td>Homozygous p.Ser171del c.512_514delCCT</td>
<td>Homozygous p.Ser171del c.512_514delCCT</td>
</tr>
<tr>
<td>Birth weight</td>
<td>2,800 g (-1.44 SDS)</td>
<td>2,500 g (-2.94 SDS)</td>
</tr>
<tr>
<td>Dysmorphism</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Skin abnormalities</td>
<td>Telangiectasias, hemangiommas</td>
<td>Telangiectasias</td>
</tr>
<tr>
<td>Hepatological problems</td>
<td>Splenomegaly, cryptogenic cirrhosis, portal hypertension</td>
<td>Splenomegaly, cryptogenic cirrhosis, portal hypertension</td>
</tr>
<tr>
<td>Liver transplantation</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Impaired coagulation tests</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Cytopenia</td>
<td>Leukopenia and thrombocytopenia</td>
<td>Leukopenia and thrombocytopenia</td>
</tr>
<tr>
<td>Urinary system problems</td>
<td>Primary nocturnal enuresis, hypercalcaemia, nephrolithiasis, proteinuria, chronic kidney disease</td>
<td>Primary nocturnal enuresis, hypercalcaemia, proteinuria, membranous glomerulopathy, chronic kidney disease</td>
</tr>
<tr>
<td>Cardiac problems</td>
<td>Secundum ASD, MVP, aortic regurgitation</td>
<td>Secundum ASD (surgically corrected) Bilateral cryptorchidism (orchiopexy), short stature, hypergonadotropic hypogonadism</td>
</tr>
<tr>
<td>Endocrine system problems</td>
<td>Hypergonadotropic hypogonadism</td>
<td></td>
</tr>
<tr>
<td>Mental problems</td>
<td>ADHD</td>
<td>None</td>
</tr>
<tr>
<td>At transition</td>
<td>Adult height: 165.7 cm</td>
<td>Adult height: 165 cm</td>
</tr>
<tr>
<td></td>
<td>Regular menses with HRT</td>
<td>On testosterone treatment</td>
</tr>
</tbody>
</table>

ASD: atrial septal defect, MVP: mitral valve prolapse, ADHD: attention deficit/hyperactivity disorder, HRT: hormone replacement therapy

Table 2. Clinical and hormonal profile of the cases at admission and pubertal milestones

<table>
<thead>
<tr>
<th>Tanner stage</th>
<th>Patient 1</th>
<th>P2, T1/1</th>
<th>0.6</th>
<th>0.1</th>
<th>18.5</th>
<th>-</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pubertal onset (9-10 years)</td>
<td>P2, T1/2</td>
<td>7.1</td>
<td>1.6</td>
<td>21</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Menarche (12-13 years)</td>
<td>P4, T4/4</td>
<td>18</td>
<td>11.1</td>
<td>29.6</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Secondary amenorrhea (13-14 years)</td>
<td>P5, T5/5</td>
<td>56.2</td>
<td>33.5</td>
<td>15.6</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Patient 2</td>
<td>P1, bilateral NP tests</td>
<td>3.4</td>
<td>0.23</td>
<td>-</td>
<td>&lt;0.01</td>
<td></td>
</tr>
<tr>
<td>At the time of pubertal delay (14 years)</td>
<td>P2, TV 0.5-0.5 mL</td>
<td>128</td>
<td>88.8</td>
<td>-</td>
<td>0.28</td>
<td></td>
</tr>
</tbody>
</table>